Welcure Drugs And Pharmaceuticals Share Price Hits Upper Circuit On Stock Split And Bonus Issue Proposal

Welcure Drugs and Pharmaceuticals Limited was in focus on August 11, 2025. The stock was in focus after the company informed the exchanges about its upcoming board meeting to consider significant corporate actions. 

Board Meeting Scheduled To Consider Corporate Actions

The company has scheduled a board meeting on Friday, August 22, 2025. On the agenda are 2 key proposals: a stock split and a bonus share issue. Both actions are subject to board approval, necessary statutory clearances and shareholder consent.

Proposed Stock Split In Ratio Of 1:10

Welcure Drugs and Pharmaceuticals is considering subdividing its equity shares in the ratio of 1:10. This means one existing equity share could be split into ten smaller shares, increasing the total number of shares in circulation. If approved, this is expected to improve share affordability and broaden investor participation.

Proposed Bonus Issue Up To 1:1

In addition to the stock split, the board will also deliberate on issuing bonus shares up to 1:1. This means one bonus equity share could be issued for every one share held, subject to the availability of adequate reserves and necessary approvals.

Objective Behind The Proposals

According to the company, the primary aim of these proposals is to enhance liquidity, broaden the shareholder base and make the shares more accessible to a wider pool of investors. Detailed timelines, record dates and sequences of actions will be announced once approvals are obtained.

Welcure Drugs and Pharmaceuticals Share Price Performance

Welcure Drugs and Pharmaceuticals share price touched the upper circuit of 5% at 11:18 AM on August 11, 2025. 

Read More: HG Infra Engineering JV Secures ₹2,195.68 Crore Order from Rail Land Development Authority! 

Conclusion

The proposals are still under consideration and await necessary approvals. Investors will have to wait for the board’s decision on August 22, 2025.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities are subject to market risks. Read all related documents carefully before investing.